CoChat
Sign Up
Cited by 57Cancer, Lipids, and MetabolismHead and Neck Cancer StudiesLipoproteins and Cardiovascular Health

The DOI matches its Crossref record.

Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer

Open access
Gupta, Abhinav, Stokes, William, Eguchi, Megan, Hararah, Mohammad, Amini, Arya, Mueller, Adam, Morgan, Rustain, Bradley, Cathy, Raben, David, McDermott, Jessica, Karam, Sana D·2019·Oral Oncology
DOI 10.1016/j.oraloncology.2019.01.019PMC PMC6659746
Open this paper in CoChat — free account

Abstract

Objectives Studies have shown the utility of lipid-lowering agents in improving outcomes in various cancers. We aim to explore how statins affect overall survival and cancer specific survival in head and neck cancer patients using population-based datasets. Patients and methods Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked dataset, we separated HNC patients into three groups: those with no hyperlipidemia (nH), those with hyperlipidemia and not taking a statin (HnS), and those with hyperlipidemia and taking a statin (H + S). Overall survival (OS) and cancer specific survival (CSS) were compared between the three groups based on disease subsite (oral cavity, oropharynx, and other) using Kaplan-Meier and multivariate Cox regression analysis (MVA), controlling for demographic, socioeconomic, staging, treatment, and comorbidity covariates. Using Pearson chi-square analysis, we also compared the incidence of cancer-related toxicity events. Results There were 495 nH, 567 HnS, and 530 H + S patients. H + S patients had superior OS and CSS (73.0, 81.2%) relative to nH (58.6, 69.1%) and HnS groups (61.7, 69.2%) (p < 0.01). On MVA, H + S patients showed improved OS (p < 0.01) and CSS (p = 0.04) compared to nH (HR = 1.64, 1.56) and HnS (HR = 1.40, 1.37). MVA stratified by subsite yielded similar results for oral cavity and oropharyngeal disease. Toxicity-related events did not differ significantly between the groups. Conclusion HNC patients with hyperlipidemia and taking a statin demonstrated improved outcomes compared to nH and HnS patients, further supporting statins' role as a potential adjuvant anti-neoplastic agent in HNC. Further prospective studies to investigate the impact of statins on HNC outcomes are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.oraloncology.2019.01.019

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 20

  1. Daneshi, 2018, Effects of different treatment strategies and tumor stage on survival of patients with laryngeal carcinoma: A 15-year cohort study, J Cancer Epidemiol, 10.1155/2018/9678097 · DOI
  2. Lee, 2003, Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors, Endocrinology, 144, 2201, 10.1210/en.2003-0288 · DOI
  3. Zhu, 2016, Pubertal and adult windows of susceptibility to a high animal fat diet in Trp53-null mammary tumorigenesis, Oncotarget, 7, 83409, 10.18632/oncotarget.13112 · DOI
  4. Raza, 2017, The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERβ in prostate cancer cells, Cancer Cell Int, 17, 52, 10.1186/s12935-017-0422-x · DOI
  5. Morel, 2017, Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors, J Lipid Res, 58, 982, 10.1194/jlr.M072207 · DOI
  6. Zhou, 2017, Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC), BMC Cancer, 17, 269, 10.1186/s12885-017-3239-z · DOI
  7. Byon, 2009, Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4, Lab Invest, 89, 1221, 10.1038/labinvest.2009.97 · DOI
  8. Nielsen, 2012, Statin use and reduced cancer-related mortality, The New Engl J Med, 367, 1792, 10.1056/NEJMoa1201735 · DOI · Paper page
  9. Apostolova, 2016, Statins and alkylphospholipids as new anticancer agents targeting lipid metabolism, Anticancer Agents Med Chem, 16, 1512, 10.2174/1871520616666160624093955 · DOI
  10. Lebo, 2018, Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma, Head Neck, 40, 1697, 10.1002/hed.25152 · DOI
  11. Stokes, 2018, Survival impact and toxicity of metformin in head and neck cancer: an analysis of the SEER-medicare dataset, Oral Oncol, 84, 12, 10.1016/j.oraloncology.2018.06.022 · DOI
  12. Klabunde, 2000, Development of a comorbidity index using physician claims data, J Clin Epidemiol, 53, 1258, 10.1016/S0895-4356(00)00256-0 · DOI
  13. Chan, 2003, The statins as anticancer agents, Clin Cancer Res, 9, 10
  14. Wong, 2002, HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis, Leukemia, 16, 508, 10.1038/sj.leu.2402476 · DOI
  15. Denoyelle, 2001, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study, Carcinogenesis, 22, 1139, 10.1093/carcin/22.8.1139 · DOI
  16. Kusama, 2001, Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, Cancer Res, 61, 4885
  17. Jakobisiak, 2003, Potential antitumor effects of statins, Int J Oncol, 23, 1055
  18. Kollmeier, 2011, Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy, Int J Radiat Oncol Biol Phys, 79, 713, 10.1016/j.ijrobp.2009.12.006 · DOI
  19. Denaro, 2013, Strategies for non-resectable head and neck cancer, Curr Treat Options Oncol, 14, 492, 10.1007/s11864-013-0260-6 · DOI
  20. Kantarjian, 2013, Cancer drugs in the United States: Justum Pretium–the just price, J Clin Oncol: Official J Am Soc Clin Oncol, 31, 3600, 10.1200/JCO.2013.49.1845 · DOI

Cited by

Sorted by citations

Metadata

Authors
Gupta, A., Stokes, W., Eguchi, M., Hararah, M., Amini, A., Mueller, A., Morgan, R., Bradley, C., Raben, D., McDermott, J., & Karam, S. D.
Affiliations
  • University of Colorado Denver (US)
  • Colorado School of Public Health (US)
  • City Of Hope National Medical Center (US)
Corresponding author
Karam, Sana D
ORCID
Venue
Oral Oncology
Publisher
Elsevier BV
Published
2019-03
Volume
90
Pages
54-66
ISSN
1368-8375 (ISSN-L)
DOI
10.1016/j.oraloncology.2019.01.019
PMC
PMC6659746
OpenAlex
W2914319215
Cited by
57
References
0
Citations by year
2026: 3 · 2025: 7 · 2024: 7 · 2023: 12 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 4
FWCI
2.14
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Oral Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • University of Colorado Cancer Center (P30CA046934)
  • RSNA (RSD1713)
  • Cancer League of Colorado
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
statins, head and neck cancer, hyperlipidemia, overall survival, cancer-specific survival, lipid-lowering drugs, oral cancer, oropharyngeal cancer
MeSH terms
Aged, Aged, 80 and over, Female, Head and Neck Neoplasms, Medicare, Humans, Hyperlipidemias, Male, United States, Survival Rate, Proportional Hazards Models, Treatment Outcome, SEER Program, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review